MODAPLEX FGFR3 Mutation Kit

Features

• High Resolution: Detect 13 and distinguish 12 missense mutations in 4.5 h
• Reliable: Built-in gene expression and fragmentation controls
• User-Friendly: Easy one-step RT-PCR workflow and automated data analysis
• Efficient: Requires only 20 ng RNA extracted from FFPE samples

The MODAPLEX FGFR3 Mutation Kit is a qualitative PCR-based multiplex assay for the detection of 13 mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. The assay is designed to work with the MODAPLEX instrument using human RNA derived from formalin-fixed, paraffin-embedded (FFPE) samples. The kit was tested on bladder cancer samples during development.

The assay must be used by qualified and trained personnel in a professional laboratory environment only. Results are intended solely for research use and not for diagnostic procedures.

Biomarkers

13 mutations: R248C, S249C, G370C, S371C, Y373C, G380R, A391E, K650E, K650Q, K650M, K650T, K650N (2 variants)

Scientific Background

Fibroblast growth factor receptors (FGFRs) are a group of transmembrane receptors that contain intracellular tyrosine kinase domains. When activated by fibroblast growth factors (FGFs), these receptors trigger intracellular signaling pathways that play key roles in cell development, differentiation, survival, migration, angiogenesis, and the development of cancer. Genetic alterations in FGFRs can lead to an overactive FGFR signaling pathway, potentially causing cells to become cancerous. Among these, mutations in the FGFR3 gene are particularly common in samples of urothelial bladder cancer [1, 2].

1. Du, S. et al. Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med 20, 490–499; 10.20892/j.issn.2095-3941.2023.0137 (2023).
2. Krook, M. A. et al. Fibroblast growth factor receptors in cancer. Br J Cancer 124, 880–892; 10.1038/s41416-020-01157-0 (2021).